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EFFICACY AND SAFETY OF VINORELBINE IN HEAVILY PRETREATED RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
PATIENTS
Paris VI, Paris, France.
Introduction
Head and neck squamous cell carcinoma (HNSCC) is one of the leading causes of cancerrelated mortality in the Western world. The GLOBOCAN estimates there has been 513 000 new cases in 2012 worldwide. 1 In France, HNSCC's incidence was of 14 638 new cases in 2012 and mortality was of 4098 cases. 2 After the frontline locoregional treatment based on surgery and chemoradiotherapy, 50% of patients present a relapse. 3 In most cases, this relapse is non curable with surgery or radiation therapy. Chemotherapy is then the only therapeutic option used in a palliative intent. Common used drugs are platinum, docetaxel, paclitaxel, 5-fluorouracil (5-FU), and methotrexate. The standard first-line treatment for inoperable recurrent or metastatic HNSCC is platinum and 5FU combined with cetuximab. 4 With this regimen, median overall survival reaches 10 months. The only validated second-line chemotherapy is methotrexate with a poor response rate. 5 In platinium refractory patients, median overall survival has been estimated to 56 days with best supportive care. 6 All efforts should be made to improve the prognosis of these patients.
Vinorelbine is a cytostatic drug part of the vinca alkaloid family. Its anti-mitotic activity is caused by inhibition of microtubule polymerization during mitosis. Vinorelbine has been used in lung cancer and breast cancer for many years. 7, 8 It has been previously evaluated as first line in patients with recurrent and/or metastatic HNSCC with a response rate of 16%. 9 Combined with other drugs, vinorelbine has a modest effect in HNSCC patients. 10, 11, 12 It could be interesting to use it as a monotherapy in patients non eligible for conventional treatment because of the comorbidities or numerous previous lines of chemotherapy.
We have retrospectively reviewed efficacy and tolerance of vinorelbine as monotherapy in HNSCC patients with recurrent or metastatic disease pre-treated with at least one line of chemotherapy.
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Patients and methods
Inclusion criteria
We included in this study all patients treated with vinorelbine in our institution for a non resectable recurrent or metastatic squamous cell carcinoma of the head and neck between January 2006 and July 2013. Patients were eligible if they were 18 years of age or older and had pathologically confirmed recurrent or metastatic HNSCC. Other inclusion criteria included ineligibility for local therapy. Their medical charts were retrospectively reviewed.
Treatment
Patients were treated with vinorelbine per os at a dose of 60 mg/m² on D1, D8 and D15 with D1=D28. If the hematological tolerance was good, the dose was increased to 90 mg/m² on D1, D8 and D15 after the third cycle of treatment. For patients unable to swallow, vinorelbine was administered IV at a dose of 25 mg/m² on D1, D8 and D15. Each administration of vinorelbine was preceded by an intake of ondansetron 8 mg half an hour before. Treatment was continued until progression or unacceptable toxicity. Before each new cycle, patients had a physical examination to evaluate tolerance and efficacy of treatment. They had a blood count every week.
Assessment of safety and efficacy
Acute toxicity was evaluated by the clinician and graded at each cycle of chemotherapy according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
Tumor response was assessed by physical examination at every cycle and by computed tomography (CT) or magnetic resonance imaging (MRI) in all patients using RECIST (Response Evaluation Criteria in Solid Tumors) 3 months after the start of vinorelbine and then at 3-month intervals.
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Statistical analysis
The endpoints assessed were response to chemotherapy, progression free survival (PFS), overall survival (OS), and acute toxicity. The Kaplan-Meier method was used to estimate the PFS and OS. PFS was calculated from the first day of chemotherapy initiation until the date of tumor progression or death. OS was calculated from the first day of chemotherapy initiation until the date of death. Analyses were performed with Statview v5 software.
Results
Patient characteristics
From January 2006 through July 2013, 23 patients received vinorelbine for recurrent or metastatic HNSCC at our institution. The initial characteristics of the 23 patients analyzed in this study are reported in Table 1 . methotrexate, and one (4%) gemcitabine plus oxaliplatin (Table 2) .
Treatment delivery and safety
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Patients received a mean of 2.2 cycles (range: 1-7). Vinorelbine was mainly administered per os (78% of patients). Dose reduction was not needed.
All patients were assessable for tolerance. Treatment was stopped prematurely in one patient after two cycles because of grade 3 asthenia.
Acute toxicities are summarized in Table 3 . Anemia, diarrhea, and constipation were the most frequent side effects. The overall incidence of severe (grade 3-4) acute toxicity was low with two cases of grade 3 neutropenia (9%) and one case of grade 3 asthenia (4%). There was no case of febrile neutropenia. There was no death related to treatment.
Efficacy and survival
The median follow-up time was 3.4 months (range: 0.1-14.1 months).
Response was assessable in 16 patients. In seven patients, the response was not assessed because they received only one cycle of vinorelbine. No objective tumor response has been observed. Three patients (19%) had disease stabilization. All of them had a tumor originally located in the oropharynx. Their HPV status was unknown. Among the seven patients who received at least three cycles of vinorelbine, three had tumor stabilization (43%).
All patients have been included in survival analysis. At the time of analysis, there have been 22 deaths and 23 disease progression. The median PFS was 2.6 months and the median OS was 3.4 months (Figures 1 and 2 ). The 1-year actuarial PFS and OS rates were 0% and 4%
(95% CI, 0-8%), respectively.
Eight patients have been able to receive another line of chemotherapy after vinorelbine: three patients received methotrexate, two carboplatine, two cetuximab, and one capecitabine. Other patients received best supportive care only.
Discussion
De nos jours, le standard de traitement des cancers ORL récurrents ou métastatiques est la De nombreuses molécules ont été testées en monothérapie ou en association, comme le méthotrexate, le carboplatine, le docetaxel, le paclitaxel, la capecitabine, le pemetrexed ou le cetuximab, avec des taux de réponse variant entre 10 et 50%. Initial treatment (n ; %) Surgery Surgery followed by RT ICT followed by surgery ICT followed by surgery and RT RT ICT followed by RT 2 (9) 2 (9) 2 (9) 7 (30) 3 (13) 7 (30) Abbreviations: n, number of patients; T, tumor; N, lymphe node; RT, radiation therapy; ICT, induction chemotherapy. Abbreviations: n, number of patients Abbreviations: n, number of patients
